Nextage Therapeutics Ltd
Nextage Therapeutics Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. It offers CellDetect, a diagnostic platform for early cancer detection, including bladder cancer, cervical cancer, and prostate cancer. The company also provides BRONJ Test, a test for bisphosphonate-related osteonecrosis of the jaw. In addition, it offers gene expression, and biomark… Read more
Market Cap & Net Worth: Nextage Therapeutics Ltd (MCTC)
Nextage Therapeutics Ltd (TA:MCTC) has a market capitalization of $471.82K (ILA175.99 Million) as of March 19, 2026. Listed on the TA stock exchange, this Israel-based company holds position #42485 globally and #401 in its home market, demonstrating a -3.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nextage Therapeutics Ltd's stock price ILA77.50 by its total outstanding shares 2270820 (2.27 Million).
Nextage Therapeutics Ltd Market Cap History: 2015 to 2025
Nextage Therapeutics Ltd's market capitalization history from 2015 to 2025. Data shows change from $30.44 Million to $471.82K (-33.92% CAGR).
Nextage Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nextage Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
17.63x
Nextage Therapeutics Ltd's market cap is 17.63 times its annual revenue
0.52x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $12.25 Million | $28.00K | -$8.75 Million | 437.47x | N/A |
| 2017 | $7.67 Million | $405.00K | -$5.73 Million | 18.94x | N/A |
| 2018 | $4.92 Million | $383.00K | -$8.73 Million | 12.84x | N/A |
| 2019 | $5.24 Million | $297.00K | -$2.09 Million | 17.63x | N/A |
Competitor Companies of MCTC by Market Capitalization
Companies near Nextage Therapeutics Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Nextage Therapeutics Ltd by market ranking:
- Tsumura & Co (MU:TSUA): Ranked #5670 globally with a market cap of $1.58 Billion USD ( €1.54 Billion EUR).
- Lavipharm S.A (AT:LAVI): Ranked #19096 globally with a market cap of $81.48 Million USD ( €79.37 Million EUR).
- Medicon Hellas S.A. (AT:MEDIC): Ranked #43505 globally with a market cap of $24.44K USD ( €23.81K EUR).
- NGRD3F (SA:NGRD3F): Ranked #42486 globally with a market cap of $45.04K USD ( R$274.28K BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5670 | Tsumura & Co | MU:TSUA | $1.58 Billion | €23.60 |
| #19096 | Lavipharm S.A | AT:LAVI | $81.48 Million | €1.24 |
| #43505 | Medicon Hellas S.A. | AT:MEDIC | $24.44K | €2.44 |
| #42486 | NGRD3F | SA:NGRD3F | $45.04K | R$29.00 |
Nextage Therapeutics Ltd Historical Marketcap From 2015 to 2025
Between 2015 and today, Nextage Therapeutics Ltd's market cap moved from $30.44 Million to $ 471.82K, with a yearly change of -33.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | ILA471.82K | +0.65% |
| 2024 | ILA468.78K | +127.14% |
| 2023 | ILA206.38K | -42.54% |
| 2022 | ILA359.19K | -74.68% |
| 2021 | ILA1.42 Million | -23.93% |
| 2020 | ILA1.86 Million | -64.38% |
| 2019 | ILA5.24 Million | +6.44% |
| 2018 | ILA4.92 Million | -35.87% |
| 2017 | ILA7.67 Million | -37.38% |
| 2016 | ILA12.25 Million | -59.76% |
| 2015 | ILA30.44 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Nextage Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $471.82K USD |
| MoneyControl | $471.82K USD |
| MarketWatch | $471.82K USD |
| marketcap.company | $471.82K USD |
| Reuters | $471.82K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.